Efficacy of Spinal Muscular Atrophy Therapies Depends on Early Initiation

Spinal Muscular Atrophy Remains Controlled in a Phase 3 Study with New Gene Therapy: SPR1NT Trial

Cognitive Function as an Endpoint in Secondary Progressive Multiple Sclerosis

Targeted Agent Found Better than Immunomodulator as First-Line Strategy for Relapsing Multiple Sclerosis

Extended Protection from Disability and Cognitive Dysfunction
Seen in Active SPMS

Relapsing-Remitting Multiple Sclerosis and High-efficacy Therapies

Relapsing-Remitting Multiple Sclerosis: Oral First-line Immunomodulators

Delays in Progression of Secondary-Progressive Multiple Sclerosis Persist at 5 years

New Long-term Data Supports Early Intensive Therapy in RRMS patients

Sensitive Tool Identified for Early Detection of Alzheimer’s Disease